 |
(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide |
|---|---|
| Trade Name | |
| Orphan Indication | Circadian rhythm sleep disorders in blind people with no light perception |
| USA Market Approval | USA |
| USA Designation Date | 2001-10-03 00:00:00 |
| Sponsor | Phase 2 Discovery, Inc.;3130 Highland Avenue, Third Floor;Cincinnati, Ohio, 45219 |
